A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study

@article{Yang2014ACO,
  title={A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study},
  author={Jiao Yang and Carlos R Vallarino and Morgan Bron and Alfonso T. Perez and Huifang Liang and Guiandre Joseph and Shawn S. Yu},
  journal={Current Medical Research and Opinion},
  year={2014},
  volume={30},
  pages={2223 - 2231}
}
Abstract Objectives: The objectives of this study were to assess and compare all-cause mortality rates between pioglitazone (PIO) and insulin (INS). Research design: The study population included 56,536 patients with type 2 diabetes aged ≥45 years who were first-time users of PIO or INS. Data from 1 May 2000 until 30 June 2010 from the i3 InVision Data Mart database were linked to death records of the US Social Security Administration obtained in March 2012, with approval from the Institutional… 

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study

It is suggested that pioglitazone is associated with a decrease in both cardiovascular and non-cardiovascular mortality, and a protective effect associated with piog litazone was also found for all specific cardiovascular causes.

Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study

In this large observational cohort study of patients with type 2 diabetes, pioglitazone exposure was associated with a statistically significant decrease in the risk of all-cause mortality across four European countries.

An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

Alogliptin improves glycemic control and appears neutral in terms of cardiovascular events and use of the combination may permit the use of lower doses of pioglitazone with reduced adverse effects, and there are no cardiovascular outcome studies with the combination.

An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes.

There are no cardiovascular outcome studies with the combination but the cardiovascular benefits of pioglitazone and additional glucose lowering effects of alogliptin provide a useful combination with convenient once daily dosing.

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

Pioglitazone is a potent insulin sensitizer, preserves beta-cell function, causes durable reduction in HbA1c, corrects multiple components of metabolic syndrome and improves nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: improvement of lipid metabolism

Besides preventing a modest negative effect of n-3 fatty acids on glycemic control, the combination of pioglitazone and EPA + DHA can be used to improve lipid metabolism in T2D patients on stable metformin therapy.

References

SHOWING 1-10 OF 30 REFERENCES

Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights

Compared with insulin, pioglitazone was associated with a significant reduction in the risk of MI and stroke requiring hospitalization, and a significant Reduction in therisk of other selected cancers, while piog litazone treatment may be linked with a lower risk of bladder cancer and bone fracture relative to insulin.

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

Overall, ever use of pioglitazone was associated with an increased rate of bladder cancer among people with type 2 diabetes, and the rate increased as a function of duration of use.

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

In this cohort of diabetic patients from France, pioglitazone exposure was significantly associated with increased risk of bladder cancer.

Pioglitazone and bladder cancer: a propensity score matched cohort study.

The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes.

Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.

Overall, diabetes and MI were similarly strong predictors of total mortality, whereas prior MI was more strongly predictive of coronary mortality than diabetes at any age and level of cardiovascular risk factors.

Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes

No clear evidence of an association between use of pioglitazone and risk of the incident cancers examined is found, and longer-term studies are needed.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

A relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined is suggested; although this requires replication in other studies, it may have implications for prescribing within this class of drugs.

Mortality Experience of a Low-Income Population With Young-Onset Diabetes

Excess mortality persists among people with young-onset diabetes of long duration, with ESRD and CAD as the leading contributors to mortality.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Compared with prescription of pioglitazone, prescription of rosig litazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increase risk of the composite of AMI, stroke,heart failure, or all- cause mortality in patients 65 years or older.